NFKB1 and Patent ductus arteriosus: According to the literature and our own observations, highly gemcitabine-resistant, aggressive PDA cells possess higher NF-κB activity compared to more sensitive PDA cells [43], reflecting the role of NF-κB in conferring CSC features [11].